Price$4.27-0.16 (-3.61%)
01:30 PM05:45 PM
News · 26 weeks40+700%
2026-01-182026-07-12
Mix2290d
- SEC Filings12(55%)
- Other5(23%)
- Insider5(23%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)
- INSIDERDirector Tinmouth Brian Philippe was granted 2,875 shares, increasing direct ownership by 31% to 12,125 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Macdonald Guy was granted 2,875 shares, increasing direct ownership by 29% to 12,625 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Anido Armando was granted 2,875 shares, increasing direct ownership by 32% to 11,750 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Hastings David C was granted 2,875 shares, increasing direct ownership by 33% to 11,522 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Hanham Ann was granted 2,875 shares, increasing direct ownership by 33% to 11,577 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- PRSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator. The study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), on track for Q4 2026. "Initiating this Phase 1 study of SCY-770 marks an important milestone for SCYNEXIS as we advance a highly differentiated therapy
- SECSCYNEXIS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events8-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces One-for-Eight Reverse Stock SplitJERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026. SCYNEXIS's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS's existing trading symbol "SCYX" with a new CUSIP number, 811292 309. The reverse stock split was approved by SCYNEXIS's stockholders at SCYNEXIS's Special Meeting hel
- PRSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateCompleted transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1stSCYNEXI
- SECSEC Form 10-Q filed by SCYNEXIS Inc.10-Q - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form EFFECT filed by SCYNEXIS Inc.EFFECT - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form 424B3 filed by SCYNEXIS Inc.424B3 - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company's Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee's acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were
- SECSEC Form S-3 filed by SCYNEXIS Inc.S-3 - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form DEF 14A filed by SCYNEXIS Inc.DEF 14A - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form DEFA14A filed by SCYNEXIS Inc.DEFA14A - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form DEF 14A filed by SCYNEXIS Inc.DEF 14A - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form PRE 14A filed by SCYNEXIS Inc.PRE 14A - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Leadership Update8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form PRE 14A filed by SCYNEXIS Inc.PRE 14A - SCYNEXIS INC (0001178253) (Filer)
- INSIDERSEC Form 4 filed by Angulo Gonzalez David4 - SCYNEXIS INC (0001178253) (Issuer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
SCYX FAQ
6 questionsWhat does SCYNEXIS Inc. do?
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai)...Where does SCYX stock trade?
SCYNEXIS Inc. (SCYX) is listed on NASDAQ.What sector and industry is SCYX in?
SCYNEXIS Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did SCYNEXIS Inc. go public?
SCYNEXIS Inc. (SCYX) completed its IPO in 2014.What companies are similar to SCYX?
Notable peers in the same industry include INTT (inTest Corporation), CDTX (Cidara Therapeutics Inc.), NBSE (NeuBase Therapeutics Inc.), SACH (Sachem Capital Corp.). Compare SCYX side-by-side with any of them on Quantisnow.How can I track SCYX on Quantisnow?
Quantisnow aggregates SCYNEXIS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SCYX to receive live email and push alerts on every new disclosure.